Aktienanalyse zu Liquidia Corp (LQDA)LQDALiquidia Corp

Liquidia Corporation is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products for cardiopulmonary diseases. The Company operates within the biotechnology sector, focusing on treatments for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enables precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is a PRINT‑engineered inhaled dry‑powder formulation of treprostinil designed to enhance deep lung delivery, improve therapeutic performance, and enable higher dose administration through a convenient inhaler. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Liquidia Corp is a good buy right now due to its recent legal settlement, which has removed significant uncertainty regarding its key drug Yutrepia, leading to a 27% stock surge this week. The current price is $34.35, and analysts project a price target of $70, suggesting a potential upside of about 93%. Additionally, the gross margin has been consistently high, with 93.27% reported in Q2 2026, indicating strong profitability. However, the main risk is the high P/E ratio of 185.08, which suggests that the stock may be overvalued if future earnings do not meet expectations.

4 analysts cover LQDA: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 47.50.